Post-Partum Depression, Endometrial Cancer, mCRC, and Ebolavirus

New FDA Approvals

Contenu fourni par Emma Nichols, PhD and Emma Hitt Nichols. Tout le contenu du podcast, y compris les épisodes, les graphiques et les descriptions de podcast, est téléchargé et fourni directement par Emma Nichols, PhD and Emma Hitt Nichols ou son partenaire de plateforme de podcast. Si vous pensez que quelqu'un utilise votre œuvre protégée sans votre autorisation, vous pouvez suivre le processus décrit ici https://fr.player.fm/legal.

1y ago 8:21

MP3•Maison d'episode

Fetch error

Hmmm there seems to be a problem fetching this series right now. Last successful fetch was on July 29, 2024 20:37 (3M ago)

What now? This series will be checked again in the next hour. If you believe it should be working, please verify the publisher's feed link below is valid and includes actual episode links. You can contact support to request the feed be immediately fetched.

Check out our free downloads at nascentmc.com:

See the full write ups for today's episodes at nascentmc.com/podcast

In this week's New FDA Approval's podcast episode, Dr. Emma Hitt Nichols discusses the latest FDA approvals from July 31, 2023 – August 4, 2023. Please check back every Monday morning so that you can stay up to date.

Here are the highlights:

· The FDA has approved Zurzuvae, the first oral medication for postpartum depression, showing significant improvement in patient symptoms compared to placebo groups.

· Jemperli, a PD-1 inhibitor, has been approved by the FDA for use with chemotherapy in adult patients with primary advanced or recurrent endometrial cancer with specific mutations. The drug is already approved for use as a single agent in similar cases and is now indicated for use in the first-line setting, with discussions for a broader indication underway with the FDA.

· The FDA has approved the oral drug Lonsurf, in combination with bevacizumab, for the treatment of adult patients with metastatic colorectal cancer previously treated with specific chemotherapy and targetd therapies. Lonsurf, initially approved as a single agent in 2015, is also approved for advanced metastatic gastric or gastroesophageal junction adenocarcinoma.

· The FDA has approved an expanded indication for Ervebo, a vaccine now indicated for the prevention of disease caused by Zaire ebolavirus for individuals aged 12 months and older.

Did you know, you can access our nascentmc.com/podcast page and search the notes from this podcast! So for example, if you search a term like "diabetes" it will bring up all the diabetes related therapeutic agents approved since the first episode on May 15 of this year. We're also including the prescribing information with each summary too. Check it out at nascentmc.com/podcast.

Intro and outro music

Garden Of Love by Pk jazz Collective

60 episodes

#Fitness #Podcasting Education #Medicine #Emma Nichols, PhD #Emma Hitt Nichols